Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (Q77222399)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

title

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

A L Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

C Doershuk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

D Goldmann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

E Gore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

B Hilman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

M Marks

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

R Moss

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

B Ramsey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

G Redding

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

T Rubio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J Williams-Warren

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

R Wilmott

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

H D Wilson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

R Yogev

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

language of work or name

English

0 references

publication date

1 April 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Pediatrics

3 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

volume

134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

page(s)

413-421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

Management of pulmonary disease in patients with cystic fibrosis

3 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Selective media for the quantitation of bacteria in cystic fibrosis sputum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Standardization of lung function testing in children. Proceedings and Recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2899%2970197-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(99)70197-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10190914%20AND%20SRC:MED&resulttype=core&format=json